In our opinion, a better understanding of both the activators and silencers of inflammasomes in the TME during tumor progression (i.e., tumor cell-derived soluble factors and other molecules like lactate or ATP released by dying tumor cells) and of the intricate crosstalk between tumor and immune cells is necessary in order to define if anti-AIM2-based drugs can find therapeutic applicability. Here, AIM2 is linked to neoplasm.